Christopher Peetz
Principal executive officer pay for Christopher Peetz, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Mirum Pharmaceuticals, Inc. (MIRM) FY2022–FY2025
Beat peersTSR 305% vs peer group 39% over FY2022–FY2025
Aligned: paid up as stock roseCAP $6,502,088→$29,652,128 while $100 invested went $122.26→$495.24
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2022 | $4.4M | $6.5M |
| FY2023 | $6.5M | $9.4M |
| FY2024 | $6.6M | $13.0M |
| FY2025 | $10.4M | $29.7M |
The company's "$100 invested" index ran $122.26 at FY2022 → $495.24 by FY2025 — an annualized return of 59.4%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 59.4%/yr at MIRM ( FY2022–FY2025). See the CEO track-record ranking for context.